» Articles » PMID: 27161045

Adherence to Topical Therapies in Actinic Keratosis: A Literature Review

Overview
Publisher Informa Healthcare
Specialty Dermatology
Date 2016 May 11
PMID 27161045
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Actinic keratosis (AK) is a common skin condition, for which topical therapies are frequently prescribed. This review summarises current understanding of patient adherence and persistence to topical AK treatment by identifying literature relating to measures of adherence and persistence and influencing factors.

Methods: A multi-database literature search was conducted (2004-2015) using key search terms. Supplementary searches of pivotal clinical trials and reference lists of eligible papers were also conducted.

Results: Non-adherence and non-persistence rates varied between real-world studies (10-63% and 23-31%, respectively), with combined non-adherence and non-persistence reported as high as 88%. Methods to calculate adherence and persistence differed between studies. Adherence and persistence were generally higher in clinical trials than clinical practice. Key contributing factors to non-adherence and non-persistence to AK treatment were identified as: treatment duration, severity and persistence of local skin responses and patient confusion over treatment regimens.

Conclusion: The review highlighted a significant evidence gap regarding adherence and persistence to topical AK therapies. Combined, non-adherence and non-persistence may be as high as 88% in clinical practice, highlighting the importance of incorporating contributing factors to patient non-adherence into treatment decisions.

Citing Articles

The role of an education E-module in patient adherence and satisfaction of topical 5-fluorouracil: a pilot study.

Kitrell B, Thomas S, Sutton A Arch Dermatol Res. 2024; 316(6):245.

PMID: 38795211 DOI: 10.1007/s00403-024-02998-y.


Poor Adherence to Self-Applied Topical Drug Treatment Is a Common Source of Low Lesion Clearance in Patients with Actinic Keratosis-A Cross-Sectional Study.

Koch E, Steeb T, Bender-Sabelkampf S, Busch D, Feustel J, Kaufmann M J Clin Med. 2023; 12(11).

PMID: 37298008 PMC: 10253365. DOI: 10.3390/jcm12113813.


Approaches to Field Therapy for Actinic Keratoses: Relating Clinical Trial Results to Real-world Practice-A Commentary.

Pariser D J Clin Aesthet Dermatol. 2022; 15(4):40-43.

PMID: 35465033 PMC: 9017667.


Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome.

Ezzedine K, Painchault C, Brignone M J Mark Access Health Policy. 2020; 8(1):1829884.

PMID: 33133432 PMC: 7580760. DOI: 10.1080/20016689.2020.1829884.


Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial.

Berman B, Tyring S, Nahm W, Osterdal M, Petersen A, Siegel D J Clin Aesthet Dermatol. 2018; 10(11):26-32.

PMID: 29399258 PMC: 5774908.